Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Didier Cataldo, Renaud Louis, Alain Michils, Rudi Peché, Charles Pilette, Florence Schleich, Vincent Ninane & Shane Hanon. (2021) Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. Journal of Asthma 58:4, pages 448-458.
Read now
Read now
Kenneth M. Faulkner, Karen MacDonald, Ivo Abraham, Abdulaziz Alhossan & Christopher S. Lee. (2021) ‘Real-world’ effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis. Expert Review of Clinical Immunology 17:1, pages 73-83.
Read now
Read now
Jason K Lee, Suvina Amin, Michelle Erdmann, Atif Kukaswadia, Jelena Ivanovic, Aren Fischer & Alain Gendron. (2020) Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada. Patient Preference and Adherence 14, pages 725-735.
Read now
Read now
Hesham N. Tarraf, Hossam Hosny Masoud, Mohamed Zidan & Begad Wahba. (2020) Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population. Journal of Asthma 57:2, pages 160-166.
Read now
Read now
Karen M. MacDonald, Abhishek Kavati, Benjamin Ortiz, Abdulaziz Alhossan, Christopher S. Lee & Ivo Abraham. (2019) Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology 15:5, pages 553-569.
Read now
Read now
Stephanie Chen, Sarowar Golam, Julie Myers, Chris Bly, Harry Smolen & Xiao Xu. (2018) Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Current Medical Research and Opinion 34:12, pages 2075-2088.
Read now
Read now
Eylem Sercan Özgür, Cengiz Özge, Ahmet Ïlvan & Sibel Atış Naycı. (2013) Assessment of Long-term Omalizumab Treatment in Patients with Severe Allergic Asthma Long-term Omalizumab Treatment in Severe Asthma. Journal of Asthma 50:6, pages 687-694.
Read now
Read now
Articles from other publishers (17)
Serafeim Chrysovalantis Kotoulas, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta & Konstantinos Porpodis. (2022) Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine 12:2, pages 165.
Crossref
Crossref
Joanne E. Kavanagh, Andrew P. Hearn & David J. Jackson. (2022) A pragmatic guide to choosing biologic therapies in severe asthma. Breathe 17:4, pages 210144.
Crossref
Crossref
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Giuseppina Bertorelli, Paola Rogliani & Alfredo Chetta. (2021) Oral Corticosteroids Dependence and Biologic Drugs in Severe Asthma: Myths or Facts? A Systematic Review of Real-World Evidence. International Journal of Molecular Sciences 22:13, pages 7132.
Crossref
Crossref
Jean Bousquet, Marc Humbert, Peter G. Gibson, Konstantinos Kostikas, Xavier Jaumont, Pascal Pfister & Francis Nissen. (2021) Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies. The Journal of Allergy and Clinical Immunology: In Practice 9:7, pages 2702-2714.
Crossref
Crossref
Luis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica & Juan José Martín Villasclaras. (2019) Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics - Open 3:3, pages 333-342.
Crossref
Crossref
Gilda Varricchi, Giancarlo Marone, Giuseppe Spadaro, Michele Russo, Francescopaolo Granata, Arturo Genovese & Gianni Marone. (2019) Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Current Medicinal Chemistry 26:16, pages 2801-2822.
Crossref
Crossref
Paraskevi Katsaounou, Roland Buhl, Guy Brusselle, Pascal Pfister, Rafael Martínez, Ulrich Wahn & Jean Bousquet. (2019) Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine 150, pages 51-62.
Crossref
Crossref
Danilo Di Bona, Irene Fiorino, Marialuisa Taurino, Flavia Frisenda, Elena Minenna, Carlo Pasculli, Georgios Kourtis, Anna Simona Rucco, Andrea Nico, Marcello Albanesi, Lucia Giliberti, Luciana D'Elia, Maria Filomena Caiaffa & Luigi Macchia. (2017) Long-term “real-life” safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. Respiratory Medicine 130, pages 55-60.
Crossref
Crossref
Abdulaziz Alhossan, Christopher S. Lee, Karen MacDonald & Ivo Abraham. (2017) “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. The Journal of Allergy and Clinical Immunology: In Practice 5:5, pages 1362-1370.e2.
Crossref
Crossref
Abir Al Said, Breda Cushen & Richard W Costello. (2017) Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Therapeutic Advances in Chronic Disease 8:2-3, pages 31-45.
Crossref
Crossref
Izabela Kupryś-Lipińska, Paweł Majak, Joanna Molinska & Piotr Kuna. (2016) Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Hao-Cheng Chen, Chien-Da Huang, Erin Chang & Han-Pin Kuo. (2016) Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
I. Abraham, A. Alhossan, C. S. Lee, H. Kutbi & K. MacDonald. (2016) ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 71:5, pages 593-610.
Crossref
Crossref
Caroline Gouder, Lorna Marie West & Stephen Montefort. (2014) The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. International Journal of Clinical Pharmacy 37:1, pages 36-43.
Crossref
Crossref
Gert-Jan Braunstahl, Jan Chlumský, Guy Peachey & Chien-Wei Chen. (2013) Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy, Asthma & Clinical Immunology 9:1.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Anaesthesiology 26:2, pages 244-252.
Crossref
Crossref
Neil C. ThomsonRekha Chaudhuri. (2012) Omalizumab: Clinical Use for the Management of Asthma. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 6, pages CCRPM.S7793.
Crossref
Crossref